Dr. Yardley on Current Recommendations for ER+ Breast Cancer Treatment

Video

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

The recommendations for adjuvant endocrine therapy are still evolving and utilizes tamoxifen with premenopausal patients. The recent data with axillary dissection with access minimized (ADAM), adjuvant tamoxifen longer against shorter (ATLAS), and extending the therapy from tamoxifen from 5 to 10 years are consistent.

Oncologists are currently tailoring adjuvant endocrine therapy to each patient. Additionally, there have been mixed results from clinical trials, such as the MA17R and the NSABP-42 studies.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD